Verastem reported $66.84M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Alaunos Therapeutics USD 864K 269K Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Curis USD 14.97M 898K Mar/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Laboratory Of America USD 2.82B 695M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
TG Therapeutics USD 260.53M 7.97M Sep/2026
Verastem USD 66.84M 5.42M Mar/2026